- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 21.10. | Thessaloniki Port Authority - Preparing for Pier 6 | 237 | Thessaloniki Port Authority's H125 growth was solid, with revenues up 10.2% y-o-y, driven by strength in the container business. The H125 EBITDA margin was 45.3%, compared to 43.4% in H124. Management... ► Artikel lesen | ||
| 20.10. | OSE Immunotherapeutics - Refocusing for the next phase | 278 | OSE Immunotherapeutics' H125 results, the first since the board restructuring, reflected normalised operations typical of a clinical-stage biotech, following H124's exceptional licensing income. The... ► Artikel lesen | ||
| 20.10. | Oryzon Genomics - Making headway towards Phase III in BPD | 269 | Oryzon Genomics has announced that it has received FDA feedback on its plans for the Phase III programme in borderline personality disorder (BPD) for its lead central nervous system (CNS) drug candidate... ► Artikel lesen | ||
| 16.10. | OPAP - Bringing the team together | 645 | The proposed business combination of OPAP with its majority (51.8%) shareholder, Allwyn, via an all-share transaction provides OPAP with significantly greater scale and enhances its growth outlook as... ► Artikel lesen | ||
| 16.10. | Thrive Renewables - Results reflect UK power price normalisation | 245 | Thrive Renewables' H125 results reflect the expected transition back to normalised electricity prices, with turnover down 35% y-o-y to £9.4m (H124: £14.6m) and gross profit falling 51% to £4.3m (H124:... ► Artikel lesen | ||
| 15.10. | Theon International - Intention to acquire 9.8% stake in Exosens | 511 | Theon has agreed to acquire 9.8% of the issued shares in Exosens from existing shareholders. This is a strategic investment reflecting the strong commercial relationship between the two companies, with... ► Artikel lesen | ||
| 15.10. | discoverIE Group - Organic revenue and order growth resumes | 280 | After a long period of destocking by customers, discoverIE has reported a return to organic revenue growth, with Q226 organic revenue up 1% y-o-y and H126 up 0.5% y-o-y after previously reporting flat... ► Artikel lesen | ||
| 14.10. | Sparks - discoverIE sees return to organic growth | 257 | After a long period of destocking by customers, discoverIE has reported a return to organic revenue growth, with Q226 organic revenue up 1% y-o-y and H126 up 0.5% y-o-y (after previously reporting flat... ► Artikel lesen | ||
| 13.10. | Georgia Capital - Accelerating capital deployment | 280 | Georgia Capital (GCAP) posted strong H125 results, with NAV per share up 31% in Georgian lari and 24% in pounds sterling in total return terms, accelerating its long-term growth (five-year NAV TR in... ► Artikel lesen | ||
| 13.10. | Dialight - Back to the future | 257 | Dialight is a global leader in sustainable LED lighting for industrial applications, specifically in demanding and hazardous environments. The company's primary manufacturing facility is in Mexico and... ► Artikel lesen | ||
| 13.10. | 1Spatial - 1Streetworks prospects strengthen | 287 | 1Spatial's H1 reflected slow procurement cycles, but was supported by the company's shift to a more recurring revenue model. Strategic wins with Caltrans and UK Power Networks, along with a strong pipeline... ► Artikel lesen | ||
| 13.10. | Fevara - Targeting profitable growth | 305 | Fevara is the new name of Carr's Group, reflecting the refocusing of the business as a global leader in sustainable livestock supplements. Such supplements aim to improve digestion to enhance growth... ► Artikel lesen | ||
| 10.10. | S&U - H1 results provide positive momentum | 356 | S&U has issued interim results confirming the recovery of the business and momentum supporting full-year profit expectations. Group PBT of £15.6m was 22% higher than the prior year, driven by lower... ► Artikel lesen | ||
| 08.10. | Herantis Pharma - HER-096 clears Phase Ib, eyes Phase II | 323 | Herantis Pharma reported positive top-line results from the second part of its Phase Ib trial, evaluating lead candidate HER-096 in Parkinson's disease (PD) patients, meeting both the primary and secondary... ► Artikel lesen | ||
| 08.10. | Datatec - Excellent progress made in H126 | 336 | Datatec has seen continuing strong financial performance in H126, with growing profitability in Westcon and Logicalis International and a considerable improvement in performance for Logicalis Latin... ► Artikel lesen | ||
| 07.10. | Orell Fussli - Capital markets event in November | 193 | Orell Füssli is a diversified Swiss company operating in security printing, industrial systems, publishing, book retailing and digital identity solutions. With over 500 years of heritage, it has evolved... ► Artikel lesen | ||
| 07.10. | Percheron Therapeutics - Positive Phase I readout strengthens outlook | 370 | Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the... ► Artikel lesen | ||
| 07.10. | Recce Pharmaceuticals - Phase III Indonesian DFI trial underway | 304 | Recce has reached a key milestone with the start of patient dosing in its Phase III Indonesian-focused study of the topical gel formulation (R327G) of its lead anti-infective therapeutic drug candidate... ► Artikel lesen | ||
| 06.10. | Lamda Development - Valuation upside potential is emerging | 360 | LAMDA Development delivered a strong H125 operational and financial performance across all segments of the business. The operational malls and marinas reached new high levels of EBITDA and the Ellinikon... ► Artikel lesen | ||
| 06.10. | 1Spatial - Expansion with UK Power Networks | 298 | 1Spatial has announced a significant expansion for 1Streetworks with UK Power Networks (UKPI). The deal is worth £1.0m over 15 months, with a one-year extension option, representing a 135% uplift on... ► Artikel lesen | ||
| 03.10. | Barton Gold - Developing apace | 439 | Since our last note on 12 May, Barton has continued to aggressively develop its assets in pursuit of its ambition to produce 150koz gold per year in a two-stage 'hub and spoke' model, leveraging its... ► Artikel lesen | ||
| 02.10. | Zalaris - Moving to the next stage of growth | 333 | Zalaris has built an impressive track record over the last five years, with a revenue CAGR of 11.6% and adjusted EBIT margins growing from 7.0% to 11.0% from FY20 to FY24. The company is on track to... ► Artikel lesen | ||
| 02.10. | Greggs - Improving trend through the quarter | 340 | Greggs' Q325 trading update shows improving trading as the period progressed, following the already-flagged negative effect of July's hot weather. With a slight improvement to the outlook for cost inflation... ► Artikel lesen | ||
| 02.10. | Mendus - New strategy to include CML alongside AML | 323 | Mendus has announced a strategy update, unveiling plans to expand the application of vididencel beyond the current lead programme in acute myeloid leukaemia (AML), to chronic myeloid leukaemia (CML).... ► Artikel lesen | ||
| 02.10. | Topps Tiles - Material improvement in profitability | 337 | Topps Tiles enjoyed better momentum across all of its businesses in H225 as its strategic initiatives to drive growth in larger addressable markets combined with more favourable dynamics in some of... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .